Controlling MYC’s hyperactivity with a peptide compound
A novel peptide can suppress MYC by binding directly to it with sub-micro-molar affinity, advancing cancer drug development.
List view / Grid view
A drug target is anything within a living organism to which a drug is directed and/or binds, resulting in a change in its behaviour or function.
A novel peptide can suppress MYC by binding directly to it with sub-micro-molar affinity, advancing cancer drug development.
Contrary to popular belief, ageing is not caused by just random wear and tear of our bodies over time but is instead caused by a discrete set of biological mechanisms that we now better understand and can target with therapies. Life Biosciences are specifically focused on restoring and prolonging one’s…
Adding a biodegradable polymer at the hinge and near hinge regions of trastuzumab enabled its movement across the blood-brain barrier.
Researchers have developed a new PROTAC that activates the protein degradation system and binds to a previously inaccessible ligase.
Using tumour organoids, researchers have found a starting point for the development of a more refined PDAC drug.
One gene involved in the production of iron-sulphur clusters may be crucial for the persistence of Mycobacterium tuberculosis.
Founder and CSO of Achilles Therapeutics Dr Sergio Quezada reveals how the landmark TRACERx study has gleaned key insights that could make the difference between success and failure in immunotherapy treatment.
Using shRNA screening enabled researchers to investigate the roles of individual specific factors in maintaining the network found in AML.
The first multi-chamber cardioids derived from hiPSCs have enabled scientists to investigate heart development and defects.
New software can make protein molecules that bind with high affinity and specificity to many biomarkers, including human hormones.
Understanding the mechanisms in lung formation could develop new therapeutic approaches for respiratory conditions.
Cancer treatment may be majorly impacted by new findings about the polymerase theta-mediated end joining time DNA repair pathway.
NETs require epidermal growth factor to grow, meaning that inhibiting EGF receptors could treat these types of tumours.
The new small molecule targets the glutamate system, reducing MS-like symptoms and repairing damaged myelin in two different animal models.
Astrocyte plasticity is correlated with upregulation of the Galectin 3 protein, which may greatly contribute to biomarker discovery.